RESUMEN
We describe a case of solitary juvenile polyp of the rectum with intramucosal adenocarcinoma. A 55-year-old man presented to our hospital for evaluation after a positive fecal occult blood test. Colonoscopy revealed a pedunculated polyp of 25 mm in size which has an irregular shape and pale red color on the rectum. The polyp had a proliferation of blood vessels and an invisible surface pattern. Endoscopic mucosal resection was performed. Pathologically, it was diagnosed as a solitary juvenile polyp with intramucosal well-differentiated adenocarcinoma. When we encounter juvenile polyps, the possibility of malignancy should be taken into consideration for treatment.
Asunto(s)
Adenocarcinoma , Pólipos del Colon , Masculino , Humanos , Persona de Mediana Edad , Recto/cirugía , Recto/patología , Pólipos Intestinales/patología , Pólipos Intestinales/cirugía , Adenocarcinoma/cirugía , Adenocarcinoma/patología , Colonoscopía , Pólipos del Colon/cirugía , Pólipos del Colon/patologíaAsunto(s)
Enfermedades del Íleon/diagnóstico por imagen , Válvula Ileocecal/diagnóstico por imagen , Intususcepción/diagnóstico por imagen , Anciano de 80 o más Años , Colonoscopía , Femenino , Humanos , Enfermedades del Íleon/cirugía , Válvula Ileocecal/cirugía , Intususcepción/cirugía , Tomografía Computarizada por Rayos XRESUMEN
BACKGROUND: We aimed to determine the optimal approach with endoscopic biliary drainage (EBD) and corticosteroid (CS) for the treatment of IgG4-related sclerosing cholangitis (ISC). METHODS: To evaluate the safety of EBD for treatment of biliary stricture caused by ISC, we assessed the risk of stent dislodgement and sought to determine the most appropriate time for stent removal. We also assessed the safety of treatment with CS alone for patients with obstructive jaundice, and the rate of and risk factors for biliary tract complications. RESULTS: Sixty-nine patients with ISC treated with CS were enrolled. Twenty-eight patients (40.6%) were treated with EBD for biliary stricture before CS initiation. Intentional stent removal was performed in thirteen (46.4%) after confirming CS-induced improvement. Eleven of thirteen patients (84.6%) underwent stent removal within 1 month after CS initiation and all their stent removals were safely carried out without early (within two weeks) recurrence of obstructive jaundice. Ten of twenty-eight patients (35.7%) experienced spontaneous stent dislodgement after CS initiation, and seven (70%) of them developed stent dislodgement two weeks to two months after CS initiation. Among forty-one patients treated with CS alone without EBD, 10 patients had obstructive jaundice at the time of CS initiation and all of them achieved clinical improvement without biliary tract infection. During the follow-up, three patients (4.3%), all of whom had undergone EBD, developed bile-duct stones, while none of those treated with CS alone developed bile-duct stones (p = 0.032). Long-term biliary stenting was a risk factor for bile-duct stones. CONCLUSIONS: Biliary stent removal should be carried out within 2 weeks after CS initiation if biliary stricture improves to prevent stent dislodgement. Obstructive jaundice can be treated safely with CS alone in patients without infection. Clinicians should be aware of the possibility of bile-duct stones in patients treated with EBD.
Asunto(s)
Procedimientos Quirúrgicos del Sistema Biliar/métodos , Colangitis Esclerosante/terapia , Stents/efectos adversos , Corticoesteroides/uso terapéutico , Anciano , Conductos Biliares/cirugía , Colangitis/etiología , Colangitis Esclerosante/complicaciones , Colangitis Esclerosante/cirugía , Colestasis/complicaciones , Constricción Patológica/complicaciones , Constricción Patológica/cirugía , Remoción de Dispositivos/efectos adversos , Drenaje/efectos adversos , Femenino , Humanos , Inmunoglobulina G , Ictericia Obstructiva/tratamiento farmacológico , Ictericia Obstructiva/etiología , Ictericia Obstructiva/terapia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Esfinterotomía Endoscópica/efectos adversosAsunto(s)
Colestasis/etiología , Intususcepción/etiología , Pancreatitis/etiología , Gastropatías/etiología , Neoplasias Gástricas/complicaciones , Enfermedad Aguda , Anciano , Colestasis/diagnóstico por imagen , Humanos , Intususcepción/diagnóstico por imagen , Masculino , Pancreatitis/diagnóstico por imagen , Gastropatías/diagnóstico por imagenAsunto(s)
Neoplasias de los Conductos Biliares/diagnóstico por imagen , Neoplasias de los Conductos Biliares/cirugía , Colangiocarcinoma/diagnóstico por imagen , Colangiocarcinoma/cirugía , Ictericia Obstructiva/diagnóstico , Anciano , Neoplasias de los Conductos Biliares/patología , Procedimientos Quirúrgicos del Sistema Biliar/métodos , Biopsia con Aguja , Colangiocarcinoma/patología , Colangiografía/métodos , Conducto Colédoco/diagnóstico por imagen , Conducto Colédoco/patología , Conducto Cístico/diagnóstico por imagen , Conducto Cístico/patología , Endoscopía del Sistema Digestivo/métodos , Humanos , Inmunohistoquímica , Ictericia Obstructiva/etiología , Masculino , Medición de Riesgo , Resultado del TratamientoAsunto(s)
Adenocarcinoma/diagnóstico por imagen , Anemia Ferropénica/etiología , Lipomatosis/diagnóstico por imagen , Enfermedades Pancreáticas/diagnóstico por imagen , Neoplasias Gástricas/diagnóstico por imagen , Adenocarcinoma/patología , Anciano de 80 o más Años , Anemia Ferropénica/sangre , Pancreatocolangiografía por Resonancia Magnética , Tratamiento Conservador , Medios de Contraste/administración & dosificación , Endoscopía del Sistema Digestivo , Femenino , Gadolinio/administración & dosificación , Humanos , Hipertrofia/diagnóstico por imagen , Lipomatosis/patología , Lipomatosis/terapia , Páncreas/diagnóstico por imagen , Páncreas/patología , Enfermedades Pancreáticas/patología , Enfermedades Pancreáticas/terapia , Antro Pilórico/diagnóstico por imagen , Antro Pilórico/patología , Neoplasias Gástricas/patología , Tomografía Computarizada por Rayos X/métodosRESUMEN
BACKGROUND AND AIM: Relapse and diabetes mellitus (DM) are major problems for the prognosis of autoimmune pancreatitis (AIP). We examined the prognosis of type 1 AIP after corticosteroid therapy (CST)-induced remission in terms of relapse and DM. METHODS: The study enrolled 82 patients diagnosed with type 1 AIP who achieved remission with CST. We retrospectively evaluated the relapse rate in terms of the administration period of CST, clinical factors associated with relapse, and the temporal change in glucose tolerance. RESULTS: During follow-up, 32 patients (39.0%) experienced relapse. There was no significant clinical factor that could predict relapse before beginning CST. AIP patients who ceased CST within 2 or 3 years experienced significantly earlier relapse than those who had the continuance of CST (p = 0.050 or p = 0.020). Of the 37 DM patients, 15 patients (40.5%) had pre-existing DM, 17 (45.9%) showed new-onset DM, and 5 (13.5%) developed CST-induced DM. Patients with new-onset DM were significantly more likely to show improvement (p = 0.008) than those with pre-existing DM. CONCLUSIONS: It was difficult to predict relapse of AIP based on clinical parameters before beginning CST. Relapse was likely to occur within 3 years after the beginning of CST and maintenance of CST for at least 3 years reduced the risk of relapse. The early initiation of CST for AIP with impaired glucose tolerance is desirable because pre-existing DM is refractory to CST.
Asunto(s)
Corticoesteroides/uso terapéutico , Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/tratamiento farmacológico , Diabetes Mellitus/inmunología , Pancreatitis/diagnóstico , Pancreatitis/inmunología , Anciano , Progresión de la Enfermedad , Femenino , Humanos , Estimación de Kaplan-Meier , Masculino , Pancreatitis/tratamiento farmacológico , Pronóstico , Recurrencia , Inducción de RemisiónAsunto(s)
Anisakiasis/parasitología , Anisakis/aislamiento & purificación , Gastropatías/parasitología , Estómago/parasitología , Dolor Abdominal/etiología , Adulto , Animales , Anisakiasis/complicaciones , Dolor en el Pecho/etiología , Femenino , Gastroscopía , Humanos , Gastropatías/complicacionesAsunto(s)
Ascitis/etiología , Colecistitis/complicaciones , Enfermedades de la Vesícula Biliar/etiología , Perforación Espontánea/etiología , Anciano , Ascitis/diagnóstico por imagen , Enfermedades de la Vesícula Biliar/diagnóstico por imagen , Humanos , Masculino , Perforación Espontánea/diagnóstico por imagenAsunto(s)
Dolor en el Pecho/etiología , Enfermedades del Esófago/complicaciones , Estenosis Esofágica/etiología , Hematoma/complicaciones , Anciano , Dolor en el Pecho/diagnóstico , Enfermedades del Esófago/diagnóstico , Enfermedades del Esófago/terapia , Estenosis Esofágica/diagnóstico , Estenosis Esofágica/terapia , Esofagoscopía , Femenino , Hematoma/diagnóstico , Hematoma/terapia , Humanos , Índice de Severidad de la Enfermedad , Tomografía Computarizada por Rayos XAsunto(s)
Carcinoma de Células en Anillo de Sello/secundario , Neoplasias Meníngeas/secundario , Neoplasias Gástricas/patología , Adulto , Diagnóstico Diferencial , Progresión de la Enfermedad , Resultado Fatal , Gastroscopía , Humanos , Imagen por Resonancia Magnética , Masculino , Invasividad NeoplásicaAsunto(s)
Carcinoma Hepatocelular/terapia , Ablación por Catéter , Neoplasias Hepáticas/terapia , Cuidados Paliativos , Anciano , Carcinoma Hepatocelular/diagnóstico por imagen , Hemorragia/diagnóstico por imagen , Hemorragia/terapia , Humanos , Neoplasias Hepáticas/diagnóstico por imagen , Masculino , Rotura , UltrasonografíaRESUMEN
Although interferon (IFN)-alpha and IFN-gamma have been reported to exhibit a synergistic antiviral effect through the different signaling pathways in vitro, their therapeutic efficacy is not well defined in vivo. The current study was carried out to investigate the combined antiviral effect in a model of mouse hepatitis virus Type 2 (MHV-2) infection, in which fulminant hepatitis is developed. MHV-2 was injected intraperitoneally into 4-week-old ICR mice, IFN or the vehicle was administered intramuscularly for 5 days, and the antiviral effect was evaluated based on survival periods, liver histology, serum alanine transaminase (ALT) levels, and MHV-2 virus titers in the liver tissues. The animals in the group treated with a combination of IFN-alpha and IFN-gamma survived for longer periods than the groups treated with IFN-alpha alone and IFN-gamma alone (IFN-alpha 10(3) (IU/mouse)/-gamma 10(3) vs. IFN-alpha 10(3), P < 0.005; IFN-alpha 10(3)/-gamma 10(3) vs. IFN-gamma 10(3), P < 0.001). This is consistent with the lower levels of hepatocellular necrosis and serum ALT and the decreased titers of MHV-2 virus in the liver tissues (48 hr, P < 0.001; 72 hr, P < 0.001). These findings indicate that a combination of IFN-alpha and IFN-gamma exhibits a synergistic antiviral effect on MHV-2 infection. The biology of MHV-2 is quite different from that of human hepatitis viruses; however, these results suggest the beneficial combined therapy of IFN-alpha and IFN-gamma for the treatment of human viral hepatitis.